HALİL GÜVEN

Dr. HALİL GÜVEN

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2025 in Viruses
Verified
Journal Article
Open access
PDF file
DZDidem Doğu Zengin
Didem Doğu Zengin
DEDilek Ergün
Dilek Ergün
BYBurcu Yormaz
Burcu Yormaz
RERecai Ergun
Recai Ergun
HGHALİL GÜVEN
HALİL GÜVEN
FKFikret Kanat
Fikret Kanat
Background: This study aims to identify predictive factors for pulmonary fibrosis development in COVID-19 patients by analyzing thorax CT (computed tomography) findings, serum prolidase activity, MMP-1, MMP-7, TGF-β values, laboratory findings, and demographic characteristics. Materials and methods: The investigation involved 68 patients, both male and female, aged 18 years and older, who were volunteers and had been diagnosed with confirmed COVID-19. The pulmonologist and the radiologist evaluated the thorax CT by consensus. Patients were evaluated in two categories, group 1 and group 2, based on the status of fibrotic changes, and 3-month fibrosis scores were calculated. Findings in both lungs were calculated and noted for the lobes, considering lobar spread. Correlations between quantitative parameters were assessed with Spearman’s rho correlation coefficient. Comparisons between independent samples were evaluated using either the independent sample t-test or the Mann–Whitney U test. We evaluated the relationship between categorical variables using the Pearson chi-square test and Fisher’s exact test. Results: Serum prolidase activity, MMP-1, MMP-7, and TGF-β biomarkers were not statistically significant among groups. LDH was found to be significantly high in the group with fibrotic changes. Additionally, the group with fibrotic changes also had higher levels of fibrinogen. The percentage of neutrophils, the severity of the disease, muscle–joint pain and fatigue symptoms, and the length of hospitalization stay were correlated with the total scores of fibrosis at the third month. In the group with fibrotic changes, the duration of muscle–joint pain and fatigue symptoms and the length of hospitalization were longer than in the other group. Conclusions: The group with fibrotic changes showed an increase in biomarkers. However, this increase did not reach a statistically significant level, suggesting that the third month may be an early period for these changes. The group with fibrotic changes showed high levels of LDH, one of the most important laboratory parameters of pulmonary fibrosis risk factors, along with fibrinogen, suggesting that these parameters are valuable in predicting pulmonary fibrosis. Patients with fibrotic changes can experience specific symptoms, commonly seen in COVID-19.

12 November 2025 in Research Square
Verified
Preprint
Open access
PDF file
SSSeyit Muhammed Soycan
Seyit Muhammed Soycan
DYDUYGU İLKE YILDIRIM
DUYGU İLKE YILDIRIM
FAFikret Akyürek
Fikret Akyürek
HGHALİL GÜVEN
HALİL GÜVEN
NÜNejat Ünlükal
Nejat Ünlükal
HSHakan Serin
Hakan Serin
Objective The aim of this study is to evaluate the effects of fisetin and atorvastatin administration on metabolic parameters and adipokine, hepatokine, and myokine profiles in rats fed a high-fat diet (HFD). Additionally, the effects of these agents on liver and skeletal muscle histology were investigated. Methods In the study, male Sprague-Dawley rats were randomly divided into five groups: K(Control), Y(HFD), YF(HFD + Fisetin), YA(HFD + Atorvastatin) and YAF(HFD + Atorvastatin + Fisetin). The Y groups were fed a high-fat diet for 8 weeks. The intervention groups were administered fisetin (50 mg/kg/day) and atorvastatin (10 mg/kg/day) orally via gavage in addition to the high-fat diet for 8 weeks. At the end of the study, blood biochemistry, asprosin, fetuin-A, GDF-15, Metrnl, and histological changes in liver and gastrocnemius muscle tissue were examined. Results Histopathological examinations revealed significant structural damage in liver and muscle tissues in groups treated with HFD, while these damages were significantly reduced in the combined treatment group. However, limited effects were observed on LDL-C and TG levels in the biochemical data; an increase in total cholesterol, a decrease in glucose levels, and improvements in creatinine and urea levels were detected. No significant differences were observed in adipokine, hepatokine, and myokine levels between the groups. Conclusion The combination of fisetin and atorvastatin significantly reduced HFD-induced liver and muscle tissue damage at the histological level. In terms of biochemical parameters, the combination therapy may be protective at the tissue level, but its effects on metabolic regulation may be limited depending on the dose and duration. Therefore, pharmacodynamic interactions and optimal dosage should be investigated in more detail.

29 September 2026 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
MEMuhammed Tuğrul Ergün
Muhammed Tuğrul Ergün
MAMemduha Aydın
Memduha Aydın
RTRukiye Tekdemir
Rukiye Tekdemir
ÖBÖmer Bayırlı
Ömer Bayırlı
KGKadri Murat Gürses
Kadri Murat Gürses
MTMustafa Tezcan
Mustafa Tezcan

14 April 2026 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Open access
PDF file
FSFatma SENGÜL
Fatma SENGÜL
FAFikret Akyurek
Fikret Akyurek
HGHALİL GÜVEN
HALİL GÜVEN
FTFatma Tuncez-Akyurek
Fatma Tuncez-Akyurek
Background Psoriasis is a systemic, immune-mediated chronic disease in which the interleukin-23 (IL-23)/T-helper 17 (Th17) axis and its key effector cytokine, IL-17, play a central role. Cardiotrophin-1 (CT-1), a multifunctional cytokine from the IL-6 family, is involved in cardiovascular and metabolic homeostasis. This study aimed to evaluate serum levels of CT-1 and IL-17 in psoriasis, investigating their relationship with clinical parameters and their potential role as biomarkers for systemic inflammation and increased cardiometabolic risk. Methods This study included 64 patients diagnosed with psoriasis vulgaris and 64 age- and sex-matched healthy controls. Serum CT-1 and IL-17 levels were measured using enzyme-linked immunosorbent assay (ELISA). Disease severity was assessed using the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). Results Serum levels of both CT-1 and IL-17 were significantly higher in the psoriasis group compared to the control group (p < 0.001 for each). A strong positive correlation was found between the two cytokines (ρ = 0.890, p < 0.001). CT-1 showed stronger correlations with lipid parameters than IL-17. However, no significant correlation was observed for either cytokine with PASI or DLQI. Receiver operating characteristic (ROC) analysis demonstrated that CT-1 had stronger diagnostic accuracy (AUC: 0.915, 95% CI:0.869–0.961) for distinguishing psoriasis patients from healthy controls compared to IL-17 (AUC: 0.733, 95% CI:0.645–0.822). Conclusions This study shows that CT-1 and IL-17 levels are significantly elevated in psoriasis and suggests that this increase may be associated with systemic inflammation and dyslipidemia. The observed discriminative performance of CT-1 supports its potential relevance as a marker of systemic inflammatory and cardiometabolic involvement, although its clinical utility requires further clarification.

17 July 2026 in Bratislava Medical Journal
Verified
Journal Article
Closed access
PDF file
SSSeyit Muhammed Soycan
Seyit Muhammed Soycan
DYDUYGU İLKE YILDIRIM
DUYGU İLKE YILDIRIM
FAFikret Akyürek
Fikret Akyürek
HGHALİL GÜVEN
HALİL GÜVEN
NÜNejat Ünlükal
Nejat Ünlükal
HSHakan Serin
Hakan Serin